Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Rhea-AI Summary

Medicus Pharma (NASDAQ:MDCX) will host a live fireside chat on March 19, 2026 to review positive Phase 2 SkinJect (SKNJCT-003) topline results.

Key data: 73% clinical clearance in the 200-µg D-MNA arm at Day 57 versus 38% in the device-only P-MNA control, supporting further development and regulatory discussions.

Positive

• 73% clinical clearance in 200-µg D-MNA arm at Day 57
• 35 percentage-point separation between 200-µg drug and device arms (73% vs 38%)
• Decision-grade evidence cited to advance SkinJect toward regulatory discussions

Negative

• Small per-arm sample sizes (16 patients in most arms) limit statistical power
• 38% clinical clearance in device-only arm indicates notable biological activity without drug

News Market Reaction – MDCX

+0.40%

6 alerts

+0.40% News Effect

+9.2% Peak in 5 hr 39 min

+$52K Valuation Impact

$13M Market Cap

0.1x Rel. Volume

On the day this news was published, MDCX gained 0.40%, reflecting a mild positive market reaction. Argus tracked a peak move of +9.2% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $52K to the company's valuation, bringing the market cap to $13M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Clinical clearance (200 μg D-MNA, Day 57): 73% Clinical clearance (P-MNA, Day 57): 38% Clinical clearance (200 μg D-MNA, Day 29): 40% +5 more

8 metrics

Clinical clearance (200 μg D-MNA, Day 57) 73% SKNJCT-003 Phase 2 trial active cohort

Clinical clearance (P-MNA, Day 57) 38% Device-only control cohort in SKNJCT-003

Clinical clearance (200 μg D-MNA, Day 29) 40% SKNJCT-003 Phase 2 trial active cohort

Clinical clearance (P-MNA, Day 29) 33% Device-only control in SKNJCT-003

Clinical clearance (100 μg D-MNA, Day 29) 47% Lower-dose active arm in SKNJCT-003

Clinical clearance (100 μg D-MNA, Day 57) 42% Lower-dose active arm in SKNJCT-003

Patients assessed Day 29 47 patients Total across treatment arms in SKNJCT-003 table

Patients assessed Day 57 43 patients Total across treatment arms in SKNJCT-003 table

Market Reality Check

Price: $0.5000 Vol: Volume 1,272,257 is low a...

low vol

$0.5000 Last Close

Volume Volume 1,272,257 is low at 0.12x the 20-day average 10,548,562. low

Technical Shares at 0.498 are trading below the 200-day MA of 2.07, near the 52-week low 0.37 and far from the 8.94 high.

Peers on Argus

Ahead of this positive clinical update, MDCX was down 4.91% while scanner data s...

1 Up 2 Down

Ahead of this positive clinical update, MDCX was down 4.91% while scanner data show 2 peers moving down and 1 up. Sector momentum notes 2 peers with median losses of about -2.4%, indicating broader pressure alongside stock-specific news.

Previous Clinical trial Reports

5 past events · Latest: Mar 16 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 16	KOL webcast plan	Positive	-1.3%	Announcement of KOL-led webcast interpreting positive Phase 2 SkinJect data.
Mar 09	Data interpretation	Positive	+34.3%	Detailed interpretation of Phase 2 SkinJect results and regulatory partnering plans.
Mar 05	Topline data	Positive	-50.9%	Initial Phase 2 SKNJCT-003 topline showing 73% clinical and 40% histological clearance.
Jan 05	Conference preview	Positive	+0.0%	Biotech Showcase presentation preview as Phase 2 data readout and partnering near.
Dec 15	Enrollment complete	Positive	-3.2%	Completion of 90-patient enrollment in SKNJCT-003 Phase 2 BCC study.

Pattern Detected

Recent clinical-trial headlines for SkinJect have produced mixed reactions, with some strong rallies but more often negative or flat moves despite positive data, yielding an average move of -4.21% across similar events.

Recent Company History

Over the past several months, Medicus has repeatedly highlighted its SkinJect Phase 2 program. Key milestones included completion of enrollment of 90 patients in SKNJCT-003 by Dec 15, 2025 and expectations for topline results in Q1 2026. Subsequent releases in March 2026 detailed the 73% vs 38% clinical clearance split at Day 57 and described the dataset as decision-grade for regulatory dialogue and partnering. Today’s fireside chat continues that communication arc by further discussing the same Phase 2 topline results.

Historical Comparison

-4.2% avg move · Across five recent SkinJect clinical-trial updates, MDCX saw an average move of -4.21%, with both sh...

clinical trial

-4.2%

Average Historical Move clinical trial

Across five recent SkinJect clinical-trial updates, MDCX saw an average move of -4.21%, with both sharp gains and steep selloffs. Today’s fireside-chat notice fits the pattern of ongoing communication around the same Phase 2 dataset.

Clinical-trial news has progressed from completing enrollment and previewing catalysts, to topline Phase 2 SkinJect data, detailed interpretation, and now multiple forums (webcasts and fireside chats) to discuss the dataset with clinicians and investors.

Market Pulse Summary

This announcement highlights a fireside chat to discuss SKNJCT-003 Phase 2 topline results, includin...

Analysis

This announcement highlights a fireside chat to discuss SKNJCT-003 Phase 2 topline results, including 73% clinical clearance in the 200-μg arm versus 38% for device-only at Day 57 in nodular basal cell carcinoma. It reinforces earlier messages that the data are decision-grade for further development. Investors may watch for additional detail on safety, regulatory interactions, and how the company plans to leverage these results in future partnerships or studies.

Key Terms

phase 2, randomized, double-blind, microneedle, +3 more

7 terms

phase 2 medical

"The SKNJCT-003 Phase 2 study is a "randomized, double-blind, three-arm Phase 2 study"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

randomized medical

"The SKNJCT-003 Phase 2 study is a "randomized, double-blind, three-arm Phase 2 study"

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

double-blind medical

"The SKNJCT-003 Phase 2 study is a "randomized, double-blind, three-arm Phase 2 study"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

microneedle medical

"two dose levels of microneedle-mediated delivery of doxorubicin compared with a device-only control"

A microneedle is a tiny, often patch-like array of microscopic needles designed to deliver drugs, vaccines or other substances through the outer layer of the skin with minimal pain. Think of it as a bandage with very fine pins that bypass the skin barrier to release medicine directly where it can be absorbed faster and more reliably. Investors care because microneedle technology can create new product formats, improve patient uptake, reduce dosing costs and manufacturing challenges, and affect market size, regulatory pathways and intellectual property value.

doxorubicin medical

"two dose levels of microneedle-mediated delivery of doxorubicin compared with a device-only control"

Doxorubicin is a widely used chemotherapy drug that kills rapidly dividing cancer cells by interfering with their ability to copy genetic material, somewhat like gumming up the photocopier so abnormal cells cannot reproduce. For investors, doxorubicin matters because its clinical effectiveness, safety profile, patent status, manufacturing capacity, and pricing directly affect drugmakers’ revenue, regulatory risk, and demand for related therapies or alternative treatments.

basal cell carcinoma medical

"in patients with nodular basal cell carcinoma.Previously reported Topline results"

A type of skin cancer that starts in the cells at the bottom layer of the skin and usually grows slowly and stays local rather than spreading to other organs. It matters to investors because its high frequency and generally surgical treatment drive steady demand for diagnostics, procedures, topical or surgical products, and follow‑on therapies, while new drugs, devices or regulatory approvals can shift market value and reimbursement dynamics. Think of it as a common maintenance issue whose repair options and costs influence healthcare spending and related businesses.

histological medical

"40% histological clearance (CR) at Day 57 in 200μg Cohort"

Relating to the microscopic study of tissues, histological describes how cells and tissue structures look when viewed under a microscope. For investors, histological results can confirm whether a drug or medical procedure actually changes disease tissue or causes harm — like inspecting the weave of fabric to spot repairs or tears — and those findings often influence trial outcomes, regulatory decisions, and commercial prospects.

AI-generated analysis. Not financial advice.

Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.

PHILADELPHIA, PA / ACCESS Newswire / March 18, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, announced today that members of its executive management team, led by Dr. Raza Bokhari, Executive Chairman & CEO, will participate in a live fireside chat on Thursday, March 19, 2026, hosted by Kumaraguru (Kumar) Raja, Ph.D., Senior Biotechnology Analyst at Brookline Capital Markets.

Event:	Fireside Chat with Kumar Raja, Brookline Capital Markets
Date:	Thursday, March 19, 2026
Time:	11:00 a.m. Eastern Time
Registration:	https://us06web.zoom.us/webinar/register/WN_Qk7s5UgXQUGTymwxCJvKMw

Dr. Bokhari will provide a company update including a review of the positive SkinJect^® SKNJCT-003 Phase 2 clinical trial topline results that were reported earlier this month.

Key findings of the study include 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.

The SKNJCT-003 Phase 2 study is a "randomized, double-blind, three-arm Phase 2 study evaluating two dose levels of microneedle-mediated delivery of doxorubicin compared with a device-only control in patients with nodular basal cell carcinoma.

Previously reported Topline results of the clinical clearance of study are tabulated below:

Table 1. Clinical Clearance by Treatment Arm

Treatment Arm	# of patients (47)	Clinical clearance (Day 29)	# of patients (43)	Clinical Clearance (Day 57)
200 μg D-MNA	15	40%	15	73%
P-MNA	15	33%	16	38%
100 μg D-MNA	17	47%	12	42%

P-MNA: Microneedle device-only control arm
D-MNA: Doxorubicin-loaded microneedle array

The study results demonstrate clear separation in clinical response between the D-MNA treatment arm (73%) and P-MNA treatment arm (38%) in the 200-µg cohort at Day 57, supporting the continued development of SkinJect as a potential non-surgical treatment option for patients with basal cell carcinoma.

The dataset reflects two complementary components of the SkinJect mechanism:

1. Biologic activity from the microneedle delivery platform

2. Additional tumor-killing activity from the chemotherapeutic agent

Biological Activity of the Microneedle Device-Only Control (P-MNA)

The SKNJCT-003 study included a microneedle device-only control arm (P-MNA) that did not contain the chemotherapeutic agent. Microneedle insertion into tumor tissue is known to produce localized biological activity, including:

• mechanical disruption of tumor architecture

• activation of wound-healing pathways

• localized immune signaling

Basal cell carcinoma is recognized as a highly immunogenic tumor, and these localized biological responses are designed to contribute to tumor regression even without drug loading.

The Company previously observed similar biological effects in:

• the SKNJCT-001 Phase 1 safety study (2021)

• the interim analysis of SKNJCT-003 in March 2025

Separation Between Drug and Device Arms

The SKNJCT-003 study demonstrated substantially higher clinical clearance in the drug-loaded microneedle cohort compared with the device-only control arm atDay 57:

• 200-µg D-MNA cohort: 73% clinical clearance

• P-MNA cohort: 38% clinical clearance

Importantly, the magnitude of response observed in the active treatment cohort relative to the device-only control arm provides clinically meaningful evidence of drug-mediated therapeutic effect within a biologically active microneedle delivery platform.

The Company believes the dataset represents decision-grade evidence supporting continued development of the SkinJect program and advancement toward regulatory discussions and potential strategic partnerships.

The fireside chat will conclude with a Q&A session during which participants can ask questions. Please note this event will be live only; there will be no publicly available recording or archived webcast.

For further information contact:

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq:MDCX) is a precision-guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries across three continents.

Company's key therapeutics assets are:

SkinJect^™, a novel localized immuno-oncology precision product focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) and Gorlin Syndrome, a rare autosomal dominant disease also called nevoid BCC syndrome, collectively representing an ~$2 billion market opportunity.

Teverelix^®, a next generation GnRH antagonist is a first-in-market product for cardiovascular high-risk advanced prostate cancer patients and patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate, collectively representing an ~$6 billion market opportunity.

The Company actively engaged in following collaborations:

Skinject^™ Platform Expansion

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (MoU) with Helix Nanotechnologies, Inc. (HelixNano), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed, and there can be no assurance that such definitive agreements will be executed.

The Company is exploring co-development of thermostable infectious disease vaccines combining HelixNano's proprietary mRNA technology with the Medicus microneedle array delivery platform.

Patient Access and Advocacy

In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

In collaboration with the Gorlin Syndrome Alliance, Medicus is pursuing an Expanded Access IND program to provide Gorlin Syndrome patients with multiple or inoperable BCCs access to SkinJect^™, the Company's investigational D-MNAs, under physician supervision.

AI Enabled Clinical Development

In December 2025, the Company signed a non-binding letter of intent to collaborate with Reliant AI Inc., a decision-intelligence company specializing in generative AI for the life sciences, to develop an AI-driven clinical data analytics platform to support capital-efficient and time-efficient clinical development through data-driven dynamic clinical-site selection, pharmacodynamic (PD) informed patient stratification, and enrollment forecasting. The initial phase of the collaboration is expected to support the upcoming Teverelix clinical study planned for 2026. There can be no assurance that a definitive agreement will be executed or that the proposed collaboration will proceed as contemplated.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company's leadership and prospects, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect^™), ability to be approved for the Expanded Access IND Program to enable those suffering with Gorlin Syndrome to access SkinJect™ under physician-supervised treatment protocols, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr, high CV risk prostate cancer, women's health indications like endometriosis, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano's proprietary mRNA vaccine platform with Medicus's proprietary microneedle array (MNA) delivery platform, the Company's aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, including with respect to the Company's submission for approval in the FDA Commissioner's National Priority Voucher program, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the Company's expectations regarding reported efficacy findings and whether there will be material changes to its reported SKNJCT-003 topline results and to secure an EOP2 meeting with the FDA in the first half of 2026, entry into definitive documents with Reliant and the expected terms thereof, engaging in proposed Medicus-sponsored studies currently contemplated in the Reliant non-binding letter of intent and the expected benefits thereof, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "could," "designed," "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", "potential" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2024 (the "Annual Report"), and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SOURCE: Medicus Pharma Ltd

View the original press release on ACCESS Newswire

FAQ

What SkinJect Phase 2 topline results did Medicus (MDCX) report on March 18, 2026?

According to Medicus the SKNJCT-003 Phase 2 showed 73% clinical clearance in the 200-µg D-MNA arm at Day 57. The device-only P-MNA arm had 38% clearance, demonstrating separation between drug-loaded and device-only cohorts.

When and how can investors attend Medicus (MDCX) fireside chat about SkinJect results?

Medicus will host a live fireside chat on March 19, 2026 at 11:00 a.m. ET. According to Medicus registration is via the provided webinar link and the event will be live only, with no archived recording.

How large was the difference between drug-loaded and device-only arms in Medicus (MDCX) Phase 2 SkinJect study?

According to Medicus the 200-µg cohort showed a 35 percentage-point advantage (73% vs 38%) at Day 57. This separation is presented as evidence of drug-mediated therapeutic effect on top of device biology.

What does the 38% clearance in the P-MNA control arm mean for SkinJect (MDCX) efficacy interpretation?

According to Medicus the P-MNA device-only arm produced 38% clinical clearance, indicating microneedle insertion has biological activity that can contribute to tumor regression without drug loading.

Are Medicus (MDCX) Phase 2 SKNJCT-003 results sufficient to move toward regulatory discussions?

According to Medicus the company considers the SKNJCT-003 dataset decision-grade evidence to support continued development and initiation of regulatory discussions and potential strategic partnerships.